Re: Tamoxifen for the prevention of breast cancer: Current status of the national surgical adjuvant breast and bowel project P-1 study [4]

Journal of the National Cancer Institute

Volumn 98, Issue 9, 2006, Pages 643-

  Cuzick, Jack ^a   Forbes, John F ^b   Howell, Anthony ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR; PLACEBO;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CLINICAL PRACTICE; CLINICAL TRIAL; DATA ANALYSIS; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; LETTER; MEDICAL DECISION MAKING; METHODOLOGY; PATIENT ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; INCIDENCE; NOTE; STANDARD; CANCER MORTALITY; DRUG EFFICACY; INFORMED CONSENT; RISK BENEFIT ANALYSIS; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CONTROLLED CLINICAL TRIALS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; RESEARCH DESIGN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; UNITED STATES;

EID: 33646440021     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj167     Document Type: Letter

References (7)

1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
2. Cuzick J, Howell A, Forbes J. Early stopping of clinical trials. Breast Cancer Res 2005;7:181-3.
3. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002;360:817-24.
4. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
5. Baum M, Budzar AU, Cuzick J, Foster J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002;359:2131-9.
6. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998;352:98-101.
7. Cuzick J, Wang DY, Bulbrook RD. The prevention of breast cancer. Lancet 1986;1:83-6.